This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Imprimis Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing proprietary compounded drug therapies to physicians and patients in the United States.View IMMY
Imprimis Pharmaceuticals Inc - IMMY - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Imprimis Pharmaceuticals Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate IMPRIMIS PHARMACEUTICALS INC (IMMY) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk.